Financial reports
ARS
2023 FY
Annual report to shareholders
18 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
10 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Invivyd Announces CEO Transition
12 Apr 24
8-K
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
4 Apr 24
8-K
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Mar 24
8-K
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDAâ„¢ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
22 Mar 24
8-K
Index to Consolidated Financial Statements
9 Feb 24
8-K
Other Events
8 Jan 24
8-K
Other Events
3 Jan 24
8-K
Entry into a Material Definitive Agreement
22 Dec 23
8-K
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial
18 Dec 23
8-K
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
9 Nov 23
Registration and prospectus
S-3
Shelf registration
9 Feb 24
424B5
Prospectus supplement for primary offering
22 Dec 23
D
$23.75 mm in equity / options / securities to be acquired, sold $23.75 mm, 1 investor
29 Nov 22
S-3
Shelf registration
28 Sep 22
S-8
Registration of securities for employees
13 May 22
S-8
Registration of securities for employees
23 Aug 21
424B4
Prospectus supplement with pricing info
6 Aug 21
S-1MEF
Registration of additional securities for an S-1
5 Aug 21
S-1/A
IPO registration (amended)
4 Aug 21
8-A12B
Registration of securities on exchange
3 Aug 21
Proxies
DEF 14A
Definitive proxy
18 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 23
DEF 14A
Definitive proxy
10 Apr 23
PRE 14A
Preliminary proxy
31 Mar 23
DEFA14C
Additional information
21 Jun 22
DFAN14A
Additional proxy materials by non-management
3 Jun 22
DEFC14C
Information statement in contested solicitation
2 Jun 22
PRER14C
Preliminary revised information
31 May 22
DEFA14C
Additional information
19 May 22
PREC14C
Preliminary information statement in contested solicitation
19 May 22
Other
EFFECT
Notice of effectiveness
6 Oct 22
CORRESP
Correspondence with SEC
3 Oct 22
UPLOAD
Letter from SEC
30 Sep 22
CORRESP
Correspondence with SEC
31 May 22
UPLOAD
Letter from SEC
27 May 22
UPLOAD
Letter from SEC
18 Apr 22
SEC STAFF
SEC staff action: Order
13 Aug 21
EFFECT
Notice of effectiveness
6 Aug 21
CERT
Certification of approval for exchange listing
5 Aug 21
CORRESP
Correspondence with SEC
3 Aug 21
Ownership
SC 13G
MAVERICK CAPITAL LTD
14 Feb 24
SC 13G
Deep Track Capital, LP
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Julie Green
26 Jan 24
3
Julie Green
26 Jan 24
4
Change in insider ownership
22 Jan 24
SC 13D/A
Adimab, LLC
22 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
4
Jeremy Gowler
20 Dec 23
4
David Hering
20 Dec 23